You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

Investigational Drug Information for Centanafadine


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Centanafadine?

Centanafadine is an investigational drug.

There have been 15 clinical trials for Centanafadine. The most recent clinical trial was a Phase 3 trial, which was initiated on February 14th 2019.

The most common disease conditions in clinical trials are Attention Deficit Disorder with Hyperactivity, Hyperkinesis, and Disease. The leading clinical trial sponsors are Otsuka Pharmaceutical Development & Commercialization, Inc., Neurovance, Inc., and [disabled in preview].

There are eleven US patents protecting this investigational drug and eighty-four international patents.

Recent Clinical Trials for Centanafadine
TitleSponsorPhase
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderOtsuka Pharmaceutical Development & Commercialization, Inc.Phase 2
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3

See all Centanafadine clinical trials

Clinical Trial Summary for Centanafadine

Top disease conditions for Centanafadine
Top clinical trial sponsors for Centanafadine

See all Centanafadine clinical trials

US Patents for Centanafadine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Centanafadine ⤷  Sign Up 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders OTSUKA AMERICA PHARMACEUTICAL, INC. (Rockville, MD) ⤷  Sign Up
Centanafadine ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Centanafadine ⤷  Sign Up Crystalline compounds OTSUKA AMERICA PHARMACEUTICAL, INC. (Rockville, MD) ⤷  Sign Up
Centanafadine ⤷  Sign Up Crystalline compounds OTSUKA AMERICA PHARMACEUTICAL, INC. (Rockville, MD) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Centanafadine

Drugname Country Document Number Estimated Expiration Related US Patent
Centanafadine Australia AU2006275870 2025-07-27 ⤷  Sign Up
Centanafadine Brazil BRPI0613943 2025-07-27 ⤷  Sign Up
Centanafadine Canada CA2659215 2025-07-27 ⤷  Sign Up
Centanafadine China CN101272781 2025-07-27 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.